Background-Diabetes mellitus impairs endothelial cell (EC) function and postischemic reparative neovascularization by molecular mechanisms that are not fully understood. microRNAs negatively regulate the expression of target genes mainly by interaction in their 3Ј untranslated region. Methods and Results-We found that microRNA-503 (miR-503) expression in ECs is upregulated in culture conditions mimicking diabetes mellitus (high D-glucose) and ischemia-associated starvation (low growth factors). Under normal culture conditions, lentivirus-mediated miR-503-forced expression inhibited EC proliferation, migration, and network formation on Matrigel (comparisons versus lentivirus.GFP control). Conversely, blocking miR-503 activity by either adenovirus-mediated transfer of a miR-503 decoy (Ad.decoymiR-503) or by antimiR-503 (antisense oligonucleotide) improved the functional capacities of ECs cultured under high D-glucose/low growth factors. We identified CCNE1 and cdc25A as direct miR-503 targets which are downregulated by high glucose/low growth factors in ECs. Next, we obtained evidence that miR-503 expression is increased in ischemic limb muscles of streptozotocin-diabetic mice and in ECs enriched from these muscles. Moreover, Ad.decoymiR-503 delivery to the ischemic adductor of diabetic mice corrected diabetes mellitus-induced impairment of postischemic angiogenesis and blood flow recovery. We finally investigated miR-503 and target gene expression in muscular specimens from the amputated ischemic legs of diabetic patients. As controls, calf biopsies of nondiabetic and nonischemic patients undergoing saphenous vein stripping were used. In diabetic muscles, miR-503 expression was remarkably higher, and it inversely correlated with cdc25 protein expression. Plasma miR-503 levels were also elevated in the diabetic individuals. Conclusions-Our data suggest miR-503 as a possible therapeutic target in diabetic patients with critical limb ischemia. (Circulation. 2011;123:282-291.)
I schemic complications represent the leading cause of morbidity and mortality in diabetic patients. 1 Early in the course of diabetes, intracellular hyperglycemia causes endothelial dysfunction and microvascular rarefaction. 2 The overall result is tissue hypoperfusion, which, in limbs, results in the formation of not-healing ulcers. Moreover, diabetes mellitus impairs endogenous reperfusion accomplished by reparative angiogenesis, thereby worsening the recovery from an ischemic insult. 2 In diabetic patients, the ischemic disease follows an inexorable course, and limb amputation is too often the ultimate remedy. 2 A better understanding of the molecular mechanisms underpinning diabetes mellitus-asso-ciated vascular complications is urgently needed to improve therapeutic options. 2 
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Because of their incapacity to regulate glucose influx, endothelial cells (ECs) represent an important target for diabetes mellitus-induced damage. In particular, it is well established that ECs cultured in high glucose show delayed replication, 3, 4 abnormal cell cycling, 5 and increased apoptosis. 6 Progression through the cell cycle is a tightly regulated process that includes multiple checkpoints. An orderly ex-pression of cyclin-dependent serine/threonine kinases (cdks), their binding partners, cyclins (CCNs), and associated regulatory proteins modulates entry into each of the cell-cycle phases. In particular, CCNDs activate Cdk4 and/or Cdk6 in early G 1 phase, whereas CCNEs activate Cdk2 in the late G 1 phase, leading to the passage into the S-phase of the cell cycle. CCNA/Cdk2 complexes assure S phase progression, and CCNB/Cdk1 complexes complete mitosis (M). 7 However, among Cdks and CCNs, widespread compensations exist. 7 Phosphatases of the cell division cycle 25 family (cdc25) are critical for timely Cdk1 and Cdk2 activation, thus regulating G 1 -S and G 2 -M transitions. 8 Regulation of cellcycle progression through modulation of cdc25A, CCNE1, CCND1 and CCND2 has been reported in ECs. 9, 10 microRNA (miRNAs) are small noncoding RNAs of Ϸ22nucleotides. miRNAs are transcribed as precursors, processed by the RNase III enzymes Drosha and Dicer, and ultimately assembled into cytoplasmic protein-RNA complexes called RISCs (RNA-Induced Silencing Complexes), which mediate degradation of targeted messenger RNA (mRNA) transcripts and/or translational arrest, mainly through imperfect base pairing with the 3Ј untranslated region (3Ј-UTR). miRNAs are important regulators of gene expression. 11 Initially described for having pathogenic roles in cancer, miRNAs have become a hot-topic as biomarkers and therapeutic targets in cardiovascular diseases. 12, 13 Because a single miRNA can control multiple genes, modulation of 1 pathogenic miRNA could have a greater chance of correcting complex molecular derangements compared with targeting a specific gene. Hence, manipulation of miRNAs may open new avenues for molecular therapeutics of complex diseases, like diabetes mellitus and vasculopathies. Recently, some miRNAs have been shown to regulate EC functions implicated in angiogenesis, including EC proliferation, migration, and assembling in branched networks. 14, 15 The present study is the first to provide evidence for a role of miRNAs in diabetes mellitus-induced endothelial defects contributing to impaired postischemic angiogenesis. In fact, here we show that in vitro culture conditions mimicking diabetes mellitus and ischemia upregulate miR-503 in ECs and that, in vivo, diabetes mellitus increases miR-503 expression in ECs from ischemic limb muscles. We also show that increased miR-503 is responsible for repressed cdc25A and CCNE1 expression in ECs cultured under conditions mimicking diabetes mellitus and ischemia. Moreover, miR-503forced expression inhibited EC proliferation, migration, and network formation on Matrigel and it additionally reduced vascular smooth muscle cell (VSMC) proliferation and migration, 2 processes that are instrumental for arteriogenesis. 16 Furthermore, adenovirus-mediated local gene transfer with a decoy for miR-503 improved blood flow recovery and angiogenesis in diabetic mice with limb ischemia. Finally, miR-503 was highly expressed in both ischemic muscle specimens and the plasma of diabetic patients with critical limb ischemia. Our results suggest that miR-503 could be a novel therapeutic target in diabetic patients with peripheral ischemic complications.
Methods
An expanded version of Methods in the online-only Data Supplement includes detailed methods for the following: cells and cell culture; RNA extraction and Taq-Man Quantitative Real Time, lentivirus preparation, luciferase assays, preparation of an adenovirus for decoymiR-503 (Ad.decoymiR-503), Western blot analyses, cell cycle, cell biology assays, mouse limb ischemia and in vivo gene transfer, enrichment of ECs from limb muscles, and flow cytometry.
Cells and Cell Culture
Human umbilical vein ECs (HUVECs) and human microvascular ECs (HMVECs) were grown in EGM-2 (EBM-2 added with growth factors and other supplements) with 2% FBS. Human VSMCs cells were cultured in 10% FBS Dulbecco modified Eagles medium. To mimic hyperglycemia, ECs were incubated in 25 mmol/L D-glucose (high glucose [HG]). D-Mannitol was used as osmotic control (normal glucose condition [NG]). To mimic ischemia-induced tissue starvation, ECs were incubated in EBM-2 with 2% FBS, only (low growth factors [LGF]).
RNA Extraction and Taq-Man Quantitative Real-Time Analysis
Total RNA was extracted using TRIzol. Real-time quantification to measure miRNAs was performed with the TaqMan miRNA reverse transcription kit and miRNA assay (Applied Biosystems, Carlsbad, CA) with the DNA Engine Opticon 2 system (Bio-Rad Laboratories, Hercules, CA). miR-503 expression was normalized to the U6 small nucleolar RNA (snRU6). Primer identification numbers are: 4373228 for hsa-miR-503 and 4427975 for snRU6 (Applied Biosystems). For mRNA analysis, single-strand complementary DNA was synthesized from 1 g of total RNA. Complementary DNA was amplified by real-time polymerase chain reaction (PCR) and normalized to 18S ribosomal RNA (endogenous control). Each reaction was performed in triplicate. Quantification was performed by the 2 ⌬⌬Ct method. 17 Quantitative reverse transcription PCR (RT-PCR) was used to measure cdc25A, CCNE1, CCND1, CCND2, eGFP and 18S ribosomal RNA. RT-PCR primers are reported in the onlineonly Data Supplement.
Lentivirus Preparation and In Vitro Infection
Lentiviral vector-expressing premiR-503 (lenti.miR-503) and lenti.GFP (control) were generated. HUVECs, HMVECs and VSMCs were infected at 25 multiplicity of infection.
antimiRNA Transfection
A miR-503 inhibitor oligonucleotide (Applied Biosystems, 50 nmol/L) or a scrambled oligonucleotide was transfected into HUVECs or COS-7 cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).
Identification of Target mRNAs of miRNA-503
To determine the gene targets of miR-503, 5 leading miRNA target prediction algorithms (TargetScan 4.1, miRanda, miRbase, Diana microT 3.0, and EIMMo2) were used (online-only Data Supplement  Table IA ).
Luciferase Assays
To investigate whether miR-503 directly regulates cdc25A and CCNE1 expression, portions of the 3Ј-UTR of these potential target genes were inserted downstream of a luciferase open reading frame. CCNE1 3Ј-UTR (S204537) and cdc25A 3Ј-UTR (S213182) vectors were purchased from SwitchGear Genomics (Menlo Park, CA). For controls, we prepared similar vectors in which 5 nucleotide mutations were inserted in the 3Ј-UTR sequences (cdc25a: 675 to 681; CCNE1: 248 to 254 and 486 to 492) complementary to the miR-503 "seed" sequence. For CCNE1, plasmids with single o double mutations in 3ЈUTR were prepared. Primers and mutation sequences are reported in online-only Data Supplement Table IIA and IIB. The different luciferase constructs were transfected into COS-7 cells together with either premiR-503 or a scrambled oligonucleotide sequence (control). COS-7 cells were chosen for their high efficiency of transfection and for the absence of endogenous miR-503 expression (data not shown). Cells were cultured for 48 hours and assayed with the Dual-Luciferase Reporter Assay System (Promega, Fitchburg Center, WI). Luciferase assay for CCND1 was omitted because previously performed by others. 18 Luciferase assay for CCND2 was omitted because we found normal CCND2 protein level in HUVECs engineered to overexpress miRNA-503 (see below).
Ad.decoymiR-503 Preparation and In Vitro Infection
The decoy for miR-503 was designed using multiple copies of complementary targets. This was intended to optimize the transgene repression in the presence of the miRNA (online-only Data Supplement Methods and Figure IA ). ECs were infected with Ad.decoymiR-503 or Ad.Null (control) at 250 multiplicity of infection. To study if this titer of adenoviral vector affects EC behavior, HUVECs infected with 250 multiplicity of infection Ad.Null were compared to noninfected (PBS) HUVECs in proliferation and on Matrigel angiogenesis assays.
Western Blot Analyses
Western blots for CCND1, CCND2, CCNE1, cdc25A, and ␤-actin were performed.
Cell-Cycle Analysis
HUVECs were infected with lenti.miR-503 or lenti.GFP. After fixation in 70% ethanol and RNase A treatment, cells were stained with propidium iodide. DNA content was analyzed by flow cytometry.
BrdU Incorporation Assay
BrdU proliferation assays were performed on HUVECs, HMVECs, and VSMCs infected with lenti.miR-503 or lenti.GFP and then kept in their full media.
Adhesion Assay
At 48 hours from lentiviral infection, HUVECs were seeded on fibronectin-coated 96-well plates. One hour later, nonadherent cells were washed out and adherent cells were fixed and stained with DAPI.
Caspase-Activity Assay
Caspase-3 activity of HUVECs infected with lenti.miR-503 or lenti.GFP was measured.
Migration Scratch Assay
Migration capacities of HUVECs or VSMCs infected with lenti.miR-503 or lenti.GFP and growth arrested were measured using a scratch assay.
Matrigel Assay
HUVECs or HMVECs were infected with lentivirus and seeded in 48-well plates coated with growth factors-enriched Matrigel. Endothelial network formation was quantified by morphometry.
Mouse Limb Ischemia and In Vivo Gene Transfer
The experiments involving mice were performed in accordance with the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources and with the prior approval of the UK Home Office and the University of Bristol ethics committee.
Type-1 diabetes mellitus was induced by streptozotocin injection in CD1 male mice. Mice at 3 months of diabetes mellitus (without insulin supplementation) and nondiabetic age-and gender-matched controls were anesthetized to induce left limb ischemia. Immediately after, Ad.decoymiR-503 or Ad.Null (10 9 plaque forming units) was delivered to the ischemic adductor muscle of diabetic mice. Nondiabetic mice received Ad.Null only. The superficial blood flow (BF) of the ischemic and contralateral foot was sequentially analyzed (at 30 minutes and at 7, 14, and 21 days) by color laser Doppler (nϭat least 12 mice per group), and the ratio between BF in the ischemic foot and BF in contralateral foot was calculated and used as an index of percentage BF recovery. At 3 and 21 days postischemia, nϭ6 mice per group were euthanized for molecular biology analyses. At the latter time point, nϭ6 additional mice per group were perfusionfixed, and adductors were paraffin-embedded for histological analyses.
Capillary and arteriole densities were determined using fluorescent microscopy on sections stained with Alexa 568-conjugated isolectin-B4 (an endothelial marker) and FITC-conjugated ␣-vascular smooth actin (VSMC marker).
EC Isolation From Mouse Limb Muscles
At 3 days postischemia induction, adductor muscles of diabetic and nondiabetic mice were harvested and enzymatically digested. ECs were immunomagnetically sorted using a CD146 antibody. 19 CD146 is a transmembrane glycoprotein mainly expressed at the intercellular junction of ECs. 20 To verify, EC enrichment by our CD146positive separation, single cell suspensions were incubated with FITC-conjugated CD146 and APC-conjugated CD31 antibodies or the respective isotype for negative control. Unstained and singlestained controls were performed to define positivity. Flow cytometric analysis revealed that 82.5Ϯ2.8% of cells isolated from nondiabetic ischemic muscles coexpressed both CD146 and the classic EC marker CD31 and that diabetes mellitus does not significantly change this figure (83.4Ϯ2.9%, Pϭnot significant; online-only Data Supplement Figure II ).
Human Tissue Studies
Expressional studies were performed on plasma and on muscular specimens taken from either amputated legs of diabetic patients (nϭ11) or calf biopsies obtained during saphenous vein stripping surgery in nondiabetic patients (controls, nϭ11 
Statistical Analysis
Group differences of continuous variables were compared by 1-way ANOVA or Student t test as appropriate. Relationships between variables were determined by the Pearson correlation coefficient. Continuous data are expressed as meanϮSEM. A P value Ͻ0.05 was considered statistically significant. Analyses were performed with GraphPad Prism 5.0, SigmaStat 3.1 software (San Jose, CA). The overall false discovery rate (FDR) was estimated using the R package LBE.
Results

HG/LGF Upregulates miR-503 Expression in Cultured ECs
miR-503 was increased in both HUVECs and HMVECs cultured in HG/LGF ( Figure 1A and 1B) . Culture in HG/LGF is intended to mimic advanced diabetes mellitus when hyperglycemia is accompanied with tissue starvation.
miR-503 Impairs EC Functions
To evaluate the functional consequences of high endothelial miR-503 levels, HUVECs were infected with lenti.miR-503. Figure 2A , miR-503-forced expression impaired HUVEC cycle, thus increasing the percentage of cells in G0/G1 and reducing the percentage of cells in S and G2/M phases. The antiproliferative effect of miR-503 on HUVECs was confirmed in a BrdU incorporation assay ( Figure 2B) . Notably, miR-503-forced expression for 48 hours did not affect EC apoptosis (online-only Data Supplement Figure IVA) . The antiangiogenic potential of miR-503 was next tested in a Matrigel assay. HUVECs infected with lenti.miR-503 were impaired in their capacity to form cellular networks ( Figure 2C ). Furthermore, miR-503-overexpressing HUVECs showed reduced migratory capacity in an in vitro scratch assay ( Figure 2D ) and decreased adhesiveness to fibronectin (online-only Data Supplement Figure IVB) . Forced miR503 expression also inhibited HMVEC proliferation and tube-like structure formation in vitro (online-only 
miR-503 Directly Targets cdc25A and CCNE1
In line with data from in vitro assays, bioinformatics interrogation of genes modulated by miR-503 confirmed a functional link with expressional control of cell cycle, adhesion, migration, and angiogenesis (online-only Data Supplement Table IB ). We next analyzed putative miR-503 targets predicted by defined criteria. 21 Four targets were consistently identified by 4 out of 5 prediction softwares: cdc25A, CCND1, CCND2, and CCNE1 (online-only Data Supplement Table IA ). CCND1 has been already validated as direct target of miR-503. 18 Lenti.miR-503 reduced cdc25A and CCNE1 at mRNA and protein level in HUVECs in comparison with GFP-HUVECs. By contrast, CCND1 was downregulated at protein level only. We decided not to validate CCND2 as miR-503 target because our data indicated that its expression is not modulated by miR-503 in ECs ( Figure 3A and 3B ). As shown in Figure 3C , using luciferase assay, we validated cdc25A and CCNE1 as direct target genes of miR-503. Significant inhibition of the luciferase activity was observed in cells transfected with the constructs bearing an intact miR-503 binding site when compared with pLUC. Mutation of cdc25A target sequence prevented downregulation of luciferase activity by miR-503. For CCNE1, mutation of each conserved target sequence had only a partial effect, and mutation of both sequences fully rescued CCNE1 repression ( Figure 3C ).
Effect of miR-503 Inhibition in ECs Cultured in HG/LGF
Incubation in HG/LGF for 24 hours decreased HUVEC proliferation (Figure 4A and 4B) and networking capacity on Matrigel (Figure 4C and 4D) . In order to understand whether miRNA-503 contributes to these altered functions, we inhibited miR-503 using 2 different approaches: Ad.decoymiR-503 and antimiR503 (antisense oligonucleotide). DecoymiR-503 transcript targeting was preliminarily validated by flow cytometry, which showed a specific reduction of eGFP in COS-7 cells cotransfected with premiR-503. This was consistent with miR-503 binding to the eGFP 3Ј-UTR (onlineonly Data Supplement Figure IB Figure 4A ) and networking capacities ( Figure 4C ) under HG/LGF. Similar results were obtained with antimiR-503 ( Figure 4B and 4D) . Furthermore, Ad.decoymiR-503 restored cdc25A and CCNE1 protein expression in HG/LGF-cultured HUVECs ( Figure  4E ). Because CCND1 expression was not inhibited in HG/
LGF-cultured HUVECs (data not shown), this cyclin was not further considered.
Inhibition of miR-503 Normalizes Postischemic BF Recovery and Muscular Neovascularization in Diabetic Mice
miR-503 was remarkably higher in ischemic muscles (3 days postischemia) of diabetic mice in comparison to nondiabetic and/or nonischemic controls ( Figure 5A ). Importantly, miR-503 was expressed by CD146-positive ECs freshly isolated from murine ischemic limb muscles, with mi-R503 expression being enhanced by diabetes mellitus (Figure 5B ). Next, we tested if local miR-503 inhibition improves postischemic reparative neovascularization and blood flow recovery in diabetic mice. The capacity of Ad.decoymiR-503 to transduce limb muscles was preliminarily demonstrated by RT-PCR of the eGFP tag in Ad.decoymiR-503-injected nonischemic limb muscles of nondiabetic mice (online-only Data Supplement Figure VIII) . As expected, postischemic foot BF recovery was impaired in diabetic mice receiving Ad.Null versus nondiabetic mice given Ad.Null (Figure 5C ). Importantly, Ad.decoymiR-503 normalized BF recovery in diabetic mice ( Figure 5C ). Likewise, Ad.decoymiR-503 increased capillary and arteriolar densities in ischemic muscles of diabetic mice ( Figure 5D ). Moreover, as shown in Figure 5E , at both 3 and 21 days postischemia, cdc25A protein was downregulated by diabetes mellitus but normalized by Ad.decoymiR-503. Diabetes mellitus downregulated CCNE1 at 3 days postischemia, with this response being prevented by Ad.decoymiR-503. CCND1 expression was not modulated by diabetes mellitus (data not shown), and consequently we did not check if Ad.decoymiR-503 could alter CCND1 expression.
Expression of miR-503 and Target Genes in Human Samples
miR-503 expression was remarkably higher in limb muscles of diabetic patients undergoing major amputation for critical ischemia in comparison with calf biopsies of nondiabetic and nonischemic control subjects ( Figure 6A ). Moreover, miR-503 and cdc25A expression were inversely correlated in the diabetic patients (Pearson correlation rϭϪ0.784; Pϭ0.0025) ( Figure 6C through 6E) . By contrast, no correlation was found between miR-503 and either CCND1 or CCNE1 (data not shown). Finally, plasma levels of miR-503 were Ϸ15 times higher in diabetic patients with critical ischemia compared with control subjects ( Figure 6B ).
Discussion
miRNAs comprise a class of endogenous small noncoding RNAs that control gene expression by acting on target mRNAs for degradation and/or translational repression. Although increasing evidence indicates that miRNAs are key Figure 5 . miR-503 inhibition normalizes postischemic neovascularization and blood flow recovery in diabetic mice. Unilateral limb ischemia was induced in diabetic and nondiabetic mice. A, Relative expression (to nonischemic and nondiabetic mice) of miR-503 in ischemic (3 days postischemia) and contralateral limb muscles of diabetic and nondiabetic mice (nϭ6 per group). B, Relative expression of miR-503 in CD146-positive ECs isolated from ischemic limb muscles of diabetic and nondiabetic mice (nϭ6 per group). In A and B, miR-503 expression was normalized to snRU6 expression using the comparative Ct method. 17 Then, miR-503 expression was reported to expression in group of the nonischemic nondiabetic muscles. C and D, Ad.decoymiR-503 (decoymiR-503) or Ad.Null (Null) was delivered to the ischemic adductors of diabetic mice. Nondiabetic mice received intramuscular Ad.Null (Null). C, Line graph shows the time course of postischemic foot BF recovery (calculated as the ratio between ischemic foot BF and contralateral foot BF) in nondiabetic mice given Ad.Null (black dotted line) and in diabetic mice given either Ad.Null (red line) or Ad.decoymiR-503 (yellow line) (nϭ12 mice per group). Representative color laser Doppler images taken at 21 days postischemia induction are shown. D, Column graphs show densities of capillaries and small arterioles (diameter Ͻ50 m) in ischemic adductors at 21 days postischemia (nϭ6 per group). Representative pictures show capillaries stained by isolectin-B4 (red fluorescence) and arterioles stained by isolectin-B4 and ␣-smooth actin (green fluorescence) (original magnification 500ϫ; scale bar: 500 m). E, Representative Western blot analyses for cdc25A and CCNE1 in adductors at 3 days and 21 days postischemia (nϭ6 per group). Bar graphs show relative protein quantification of cdc25A and CCNE1. Relative values are normalized by ␣-actin levels. All values are meansϮSEM. ϩϩPϽ0.01 versus nonischemic muscle of nondiabetic mice; †PϽ0.05 and † †PϽ0.01 versus ischemic muscle of nondiabetic mice; #PϽ0.05 versus nonischemic muscle of diabetic mice; §PϽ0.05 and § §PϽ0.01 versus nondiabetic ischemic mice given Ad.Null; *PϽ0.05 and **PϽ0.01 versus diabetic ischemic mice given Ad.Null. FDR q values: 0.0375 (A); 0.0121 (C; Doppler analysis at 14 days); 0.0061 (Doppler analysis at 21 days), 0.0120 (capillary density), and 0.0252 (arteriole density) (D); 0.01921 (cdc25A; 3 days), 0.0106 (cdc25A; 21 days), and 0.0223 (CCNE1; 3 days) (E). Non Diab Isch indicates nondiabetic ischemia; Diab Isch, diabetic ischemia. players in cardiovascular disease, only minor studies have been carried out on the relationship between miRNAs and diabetes mellitus in the vascular system. One study showed that both miR-503 and miR-320 are upregulated in myocardial ECs of Goto-Kakizaki diabetic rats and that miR-320 impairs angiogenesis in vitro. 22 The other investigation reported that HG upregulates miR-221 expression in HUVECs and that miR-221 inhibits HUVEC migration in vitro. 23 In our study, we demonstrated that miR-503 is involved in diabetic endothelial dysfunction.
Constitutively low miR-503 expression in human ECs is remarkably upregulated by culture in HG/LGF to mimic advanced diabetes mellitus when hyperglycemia is accompanied by tissue starvation. Moreover, we found that mouse ECs freshly isolated from ischemic limb muscles express miR-503 and that diabetes mellitus upregulates miR-503 in these ECs. In addition, miR-503 expression was remarkably increased in ischemic muscles of both type-1 diabetic mice and diabetic patients undergoing foot amputation for critical ischemia. Plasma miR-503 was also elevated in the diabetic and ischemic patients.
We have shown that miR-503-forced expression impairs EC proliferation, migration, adhesion, and network formation capacities. miR-503 also reduced VSMC proliferation and migration, which are instrumental for arteriogenesis. 16 Conversely, miR-503 inhibition restored normal EC proliferation and in vitro angiogenesis under HG/LGF, without affecting EC function under normal culture conditions. Thus, miR-503 might be considered a suppressor of postischemic neovascularization in diabetes mellitus and a potential therapeutic target for improving healing of diabetic ischemic tissues. To gain further insights into this issue, we employed a gene therapy approach based on the adenovirus-mediated local delivery of a 3Ј-UTR decoy for miR-503 to downregulate miR-503 activity in ischemic muscles. Decoys, at least when delivered by viral vectors, can stably antagonize a miRNA without requiring multiple administrations. 24 Moreover, local injection of a decoy vector should minimize off-target effects that could follow the systemic administration of other miR-NAs inhibitors. 24 Decoys have not been previously employed in angiogenesis studies. By contrast, miRNA antisense oligonucleotides, which include cholesterol-conjugated antagomirs, have been already used to demonstrate the role of miR-92 and miR-126 in the postischemic neovascularization process in nondiabetic mice. 25, 26 Our data show that adenoviral-mediated local delivery of the miR-503 decoy normalizes postischemic muscular neovascularization and blood flow recovery in diabetic mice. To the best of our knowledge, this is the first demonstration of a therapeutic approach targeting a specific miRNA and resulting in relevant benefit for healing of limb ischemia in diabetes mellitus.
Each miRNA is believed to directly bind to and regulate the translation or stability of many target mRNAs. Recognizing these gene targets is essential before interfering with miRNA expression for therapeutic purposes. Using a Webbased computational tool developed to identify molecular pathways potentially altered by miRNAs, 27 we identified cell cycle as the main function affected by miR-503. To find the genes directly regulated by miR-503, we performed an in Figure 6 . miR-503 and cdc25A expression in human samples. A and B, Relative expression of miR-503 in plasma and limb muscles of diabetic patients with critical limb ischemia undergoing lower limb amputation and of nondiabetic and nonischemic control patients undergoing saphenous vein stripping (nϭ11 patients per group). miRNA expression was analyzed using the TaqMan Real Time PCR assay. Relative expression was calculated using the comparative Ct method. 17 Values were normalized to snRU6 expression. Values are meansϮSEM. *PϽ0.05 versus nondiabetics. C, Plasma miR-503 expression in each diabetic patient. D, Muscular miR-503 expression in each diabetic patient. E, Muscular cdc25A protein expression (assessed by Western blot) in each diabetic patient. Relative cdc25A values were obtained by normalizing for ␣-actin; F, Line graph showing the inverse correlation between muscular expression of miR-503 and cdc25A protein in diabetic patients (Pearson correlation rϭϪ0.784; Pϭ0.0045). silico analysis using 5 target prediction software programs and considering targets that were identified by at least 4 algorithms. Experimental evidence identified cdc25A, CCND1, and CCNE1 as direct targets of miR-503. However, CCND1 expression was not modulated by either HG/LGF in HUVECs or by diabetes mellitus and ischemia in vivo. Notably, miR-503 inhibition prevented cdc25A and CCNE1 downregulation in ECs cultured in HG/LGF. Similarly, Ad.decoymiR-503 normalized cdc25A and CCNE1 protein levels in the ischemic limb muscles of diabetic animals.
One of the most striking findings in this study was the dramatic increase in miR-503 expression in limb muscle of diabetic patients. Interestingly, in these human samples, miR-503 and cdc25 expression were inversely correlated. By contrast, miR-503 and CCNE1 expression did not correlate, possibly because CCNE1 is under the control of divergent transcriptional commands. 28 The high level expression of miR-503 is compatible with the advanced vasculopathy of these patients. Our data suggest that miR-503 and cdc25A may represent therapeutic targets for diabetic patients who are developing muscular ischemia. miRNAs are protected from RNAse and stable in the blood. 29 Therefore, their stability makes miRNAs concentrations well suited for being tested in patient samples as potential biomarkers of different pathological conditions. 30 In line with this insight, the plasma levels of miR-503 were dramatically increased in diabetic patients with critical limb ischemia in comparison with controls. Further studies are required to investigate miR-503 as a potential circulating biomarker of ongoing ischemia in diabetic subjects.
In conclusion, we have demonstrated that miR-503 is antiangiogenic in the context of diabetes mellitus. miR-503 is upregulated by diabetes mellitus and ischemia, and it plays a pathogenic role in the diabetes-induced impairment of reparative angiogenesis. The findings of this study highlight important clinical implications of miR-503 in diabetesassociated vascular complications.
